Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Di Maio

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Recenti Progressi in Medicina|November 1, 1981
[Congenital syphilis today]M Calvani, C Di Maio
Recenti Progressi in Medicina|March 1, 1982
[Monitoring and treatment of diabetic fetopathy]M Calvani, C Di Maio, D Ghirelli
The Journal of Antimicrobial Chemotherapy|August 1, 1992
Activity of the antimycotic ketoconazole against Helicobacter pyloriG von Recklinghausen, C di Maio, R Ansorg
Zentralblatt Fur Bakteriologie : International Journal of Medical Microbiology|September 1, 1993
Activity of antibiotics and azole antimycotics against Helicobacter pyloriG von Recklinghausen, C Di Maio, R Ansorg
Antimicrobial Agents and Chemotherapy|March 5, 2014
Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitorsV C Di Maio, V Cento, C Mirabelli, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|March 12, 2018
Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018Maria C Sorbo, Valeria Cento, Velia C Di Maio, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|April 23, 2018
Corrigendum to "Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018" [Drug Resist. Updates 37 (March) (2018) 17-39]Maria C Sorbo, Valeria Cento, Velia C Di Maio, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|April 3, 2020
Successful ongoing retreatment with glecaprevir/pibrentasvir + sofosbuvir + ribavirin in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistanceM Aragri, M Milana, V C Di Maio, et al.
Minerva Cardioangiologica|June 11, 2009
Wolff-Parkinson-White syndrome associated with Brugada syndromeG Fazio, S Augugliaro, M Lunetta, et al.
Antiviral Therapy|February 16, 2013
A boceprevir failure in a patient infected with HCV genotype 1g: importance and limitations of virus genotyping prior to HCV protease-inhibitor-based therapyValeria Cento, Simona Landonio, Francesca De Luca, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Recenti Progressi in Medicina|November 1, 1981
[Congenital syphilis today]M Calvani, C Di Maio
Recenti Progressi in Medicina|March 1, 1982
[Monitoring and treatment of diabetic fetopathy]M Calvani, C Di Maio, D Ghirelli
The Journal of Antimicrobial Chemotherapy|August 1, 1992
Activity of the antimycotic ketoconazole against Helicobacter pyloriG von Recklinghausen, C di Maio, R Ansorg
Zentralblatt Fur Bakteriologie : International Journal of Medical Microbiology|September 1, 1993
Activity of antibiotics and azole antimycotics against Helicobacter pyloriG von Recklinghausen, C Di Maio, R Ansorg
Antimicrobial Agents and Chemotherapy|March 5, 2014
Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitorsV C Di Maio, V Cento, C Mirabelli, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|March 12, 2018
Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018Maria C Sorbo, Valeria Cento, Velia C Di Maio, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|April 23, 2018
Corrigendum to "Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018" [Drug Resist. Updates 37 (March) (2018) 17-39]Maria C Sorbo, Valeria Cento, Velia C Di Maio, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|April 3, 2020
Successful ongoing retreatment with glecaprevir/pibrentasvir + sofosbuvir + ribavirin in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistanceM Aragri, M Milana, V C Di Maio, et al.
Minerva Cardioangiologica|June 11, 2009
Wolff-Parkinson-White syndrome associated with Brugada syndromeG Fazio, S Augugliaro, M Lunetta, et al.
Antiviral Therapy|February 16, 2013
A boceprevir failure in a patient infected with HCV genotype 1g: importance and limitations of virus genotyping prior to HCV protease-inhibitor-based therapyValeria Cento, Simona Landonio, Francesca De Luca, et al.
Pageof 2